All studies
RecruitingHuman Pharmacology (Phase I)- OtherInterventional

A Study to Test the Activity and Safety of Vixarelimab in Patients with Moderate to Severe Active Ulcerative Colitis

Ulcerative colitis is a long-term condition where the large bowel becomes swollen and ulcerated, causing symptoms like tummy pain, frequent diarrhoea, and bleeding. While several treatments exist, they do not work well for everyone, leaving many people in need of new options. This early-stage study is testing an investigational medicine called vixarelimab in adults with active, moderate to severe ulcerative colitis. The main aim is to check the drug's safety, see how it moves through the body, and learn if it can calm down inflammation in the gut. Because this is an early study, doctors will monitor all participants very closely with regular hospital visits and health checks. Joining the study is completely voluntary, and people can leave at any point without it affecting their normal NHS care.

At a glance

Status
Recruiting
Phase
Human Pharmacology (Phase I)- Other
Sponsor
Genentech Inc.
Enrolment target
24
Start
18 Dec 2024

What is this study about?

Ulcerative colitis is a chronic condition that causes painful inflammation and sores in the lining of the large bowel. People living with it often face sudden flares, urgent trips to the toilet, tummy cramps, and tiredness. Although standard treatments can help manage these flare-ups, many patients find that medicines stop working over time or cause unwanted side effects. Researchers are constantly looking for new ways to target the body's immune system to bring inflammation under control.

This clinical trial is looking at an experimental drug called vixarelimab. It is designed to block specific signals in the immune system that cause swelling and tissue damage in the gut. By calming these pathways, doctors hope the medicine might help heal the bowel lining and give patients relief from difficult daily symptoms.

Because this is an early-stage study, the primary focus is on safety. Scientists need to understand what happens to the drug inside the human body, what dose works best, and whether it causes any side effects. The information gathered from this study will help doctors decide whether vixarelimab should be tested in larger, later-stage clinical trials.

Key takeaways

  • Tests an experimental drug called vixarelimab for active ulcerative colitis.
  • Open to adults aged 18 and older with moderate to severe symptoms.
  • Focuses mainly on drug safety, how the body processes it, and symptom relief.
  • Requires regular clinic visits for health checks, blood tests, and symptom tracking.
  • Participation is entirely voluntary, and you can withdraw at any time.

Who may be eligible?

This study is open to adults aged 18 and over who have been diagnosed with moderate to severe ulcerative colitis. Their condition must currently be active, meaning they are experiencing noticeable symptoms despite taking standard treatments.

People might not be able to join if they have other serious health problems, such as severe heart, liver, or kidney disease, or an active infection that could make taking an experimental drug unsafe. Pregnant or breastfeeding women are usually excluded to protect the baby.

The study team will review each person's medical history, current prescriptions, and bowel health in detail before deciding if it is safe and suitable for them to take part.

Could this study suit you?

Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.

  1. I am aged 18 or over.
  2. I have been diagnosed with moderate to severe ulcerative colitis.
  3. My colitis is currently active and causing symptoms.
  4. My current treatments are not controlling my symptoms well enough.
  5. I am able to attend regular hospital appointments for check-ups and monitoring.
Answer every question to see your result.

What does participation involve?

Taking part usually involves several visits to a hospital clinic over a few months. During the study, participants will receive the study medicine, which may be given as an injection or a slow drip into a vein. Doctors will carry out regular health checks, including physical exams, blood and urine tests, and stool samples to check for gut inflammation. Some visits may also include a camera test (endoscopy) to look directly at the lining of the bowel. You will also be asked to keep a simple diary of your daily bowel symptoms. The team will follow your progress carefully throughout the trial to make sure you stay safe.

Potential risks and benefits

Taking part may not directly cure your ulcerative colitis, but it could potentially help improve your symptoms if the medicine works well for you. Your participation will also help doctors discover better treatments for other people with the condition. However, because vixarelimab is an experimental medicine, there is always a chance of side effects, such as allergic reactions, stomach upsets, or infections. You will be closely monitored, and your care team can treat any side effects that appear. Taking part is completely your choice, and you are free to leave the trial at any time without giving a reason.

Locations (1)

Some site locations are approximate. We're improving this — please verify with the trial team before travelling.
  • —
    Unverified
    Germany

Common questions

What is vixarelimab?

Vixarelimab is a new investigational drug designed to reduce inflammation by blocking specific immune signals linked to swelling in the gut.

Do I have to pay to take part?

No. The study drug, clinic visits, and all trial-related tests are provided free of charge, and travel expenses are often covered.

Will I have to stop my current colitis medication?

This depends on the specific study rules. The trial doctors will discuss your current medications and tell you whether any changes are needed.

What happens if my symptoms get worse during the study?

Your safety comes first. If your condition flares up or gets worse, the medical team will step in to provide appropriate medical care and treatment.

Can I leave the study early if I change my mind?

Yes. You have the right to withdraw from the study at any time, and this will not affect the usual medical care you receive from your GP or hospital.

How to find out more

Always speak to your GP or specialist before deciding to take part in a study.

Interested in taking part?

Register your interest

Share your details and the research team for "A Study to Test the Activity and Safety of Vixarelimab in Pa…" will contact you if you may be eligible. Always speak to your GP before agreeing to take part.

Discussion

Community discussion

Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.